Anika Therapeutics announces top-line results from CINGAL 16-02 clinical trial
Anika Therapeutics announced results from its CINGAL® 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration. While CINGAL achieved greater pain reduction numerically at every study time point, the difference did not reach statistical significance. June 19, 2018